Physician profile
Gitendra Rajiyah
NPI 1083693196
$16,520.49
in general payments reported to CMS, 2019-2025
55 companies · $2,279 in 2025
The $2,279 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,018 · 2020: $2,407 · 2021: $1,972 · 2022: $2,952 · 2023: $1,948 · 2024: $1,944 · 2025: $2,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,171.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,713.14 | 2019-2025 | |
| Abbott Laboratories | $1,604.51 | 2021-2025 | Aveir, Freestyle Libre 3, Mitraclip |
| Astrazeneca Pharmaceuticals Lp | $1,436.35 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $1,278.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,135.92 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $923.81 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $796.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $796.73 | 2019-2025 | Verquvo, Segluromet, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $647.86 | 2019-2025 | |
| Boston Scientific Corporation | $554.18 | 2019-2024 | Bodyguardian, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Lilly USA, LLC | $546.07 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $534.17 | 2019-2025 | Repatha |
| Glaxosmithkline, LLC. | $520.28 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Sunovion Pharmaceuticals INC. | $359.53 | 2019-2021 | |
| Insulet Corporation | $352.76 | 2025 | Omnipod |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitendra Rajiyah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.